John Reneau: Clinical Trials

2 trials sponsored by John Reneau, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting. 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 11Recruiting 1
Phase 21Completed 1

Follow John Reneau: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Cyclophosphamide, Fludarabine, Mogamulizumab - Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Phase 1RecruitingJohn Reneau122022-05-062026-11-16
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide - Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma
Phase 2CompletedJohn Reneau262018-03-162026-08-13

Conditions studied

Lymphoma, T-Cell, Cutaneous (2)  ·  Lymphoma, Primary Cutaneous Anaplastic Large Cell (1)  ·  Lymphoma, T-Cell (1)  ·  Lymphomatoid Papulosis (1)  ·  Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)

Interventions

Brentuximab Vedotin (1)  ·  Cyclophosphamide (1)  ·  Disulfides (1)  ·  Immunoglobulin G (1)  ·  Lenalidomide (1)  ·  fludarabine (1)  ·  mogamulizumab (1)

Countries

United States (2)

Top investigators

John C Reneau, MD, PhD (1)